%0 Journal Article
%T Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT
%A Arno Fritsch
%A Hossein-Ardeschir Ghofrani
%A John Mattson
%A Marc Humbert
%A Michael Halank
%A Michael Krowka
%A Rodrigo Cartin-Ceba
%J Pulmonary Circulation
%@ 2045-8940
%D 2018
%R 10.1177/2045894018769305
%X In patients with portopulmonary hypertension (n£¿=£¿13) included in the 12-week randomized placebo-controlled PATENT-1 trial, riociguat was well tolerated and improved 6-min walking distance (6MWD), World Health Organization functional class (WHO FC), and other efficacy parameters; 6MWD and WHO FC improvements were sustained over two years in the open-label extension, PATENT-2
%K soluble guanylate cyclase stimulator
%K portal hypertension
%K pulmonary arterial hypertension
%U https://journals.sagepub.com/doi/full/10.1177/2045894018769305